玻璃體腔注射抗血管內皮生長因子藥物治療相關非感染性視網膜血管炎1例_Chinese Journal of Ocular Fundus Diseases

Authors：

馮靖嶸 , 張愛迪 , 韓聰 , 張文芳 ,  楊義

蘭州大學第二醫院（第二臨床醫學院）眼科, 蘭州 730000;

Corresponding?author：

楊義, Email: 359111828@qq.com

Keywords：

視網膜血管炎; 抗血管內皮生長因子藥物治療; 糖皮質激素; 病例報告

DOI：

10.3760/cma.j.cn511434-20251107-00488

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 馮靖嶸, 張愛迪, 韓聰, 張文芳, 楊義. 玻璃體腔注射抗血管內皮生長因子藥物治療相關非感染性視網膜血管炎1例. Chinese Journal of Ocular Fundus Diseases, 2026, 42(4): 344-346. doi: 10.3760/cma.j.cn511434-20251107-00488 Copy

1.	Bagheri S, Ntentakis DP, Emfietzoglou M, et al. Sterile intraocular inflammation following intravitreal injections: pathogenesis, clinical features, and management[J]. Int Ophthalmol Clin, 2025, 65(3): 63-70. DOI: 10.1097/IIO.0000000000000580.
2.	Ferreira AM, Mendes AF, Beato JN, et al. Intraocular inflammation following intravitreal injections of anti-vascular endothelial growth factor drugs[J]. Graefe's Arch Clin Exp Ophthalmol, 2025, 263(10): 2885-2892. DOI: 10.1007/s00417-025-06875-w.
3.	中華醫學會眼科學分會眼底病學組, 中國醫師協會眼科醫師分會眼底病專業委員會, 《眼內注藥治療后非感染性眼內炎癥診療專家共識(2025)》專家組. 眼內注藥治療后非感染性眼內炎癥診療專家共識(2025)[J]. 中華眼底病雜志, 2025, 41(7): 492-506. DOI: 10.3760/cma.j.cn511434-20250617-00274.Fundus Disease Group of Ophthalmological Society of Chinese Medical Association, Fundus Disease Group of Ophthalmologist Branch of Chinese Medical Doctor Association, Expert Group of Expert Consensus for the Diagnosis Treatment of SterileIntraocular Inflammation after Intraocular Drug Delivery (2025). Expert consensus for the diagnosis and treatment of sterile intraocular inflammation after intraocular drug delivery (2025)[J]. Chin J Ocul Fundus Dis, 2025, 41(7): 492-506. DOI: 10.3760/cma.j.cn511434-20250617-00274.
4.	Weisbrod DJ, Kertes PJ. Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials[J]. Arch Ophthalmol, 2009, 127(2): 1581-1583. DOI: 10.1001/archophthalmol.2009.304.
5.	Goldberg RA, Shah CP, Wiegand TW, et al. Noninfectious inflammation after intravitreal injection of Aflibercept: clinical characteristics and visual outcomes[J]. Am J Ophthalmol, 2014, 158(4): 733-737. DOI: 10.1016/j.ajo.2014.06.019.
6.	Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies[J]. Ophthalmology, 2014, 121(1): 193-201. DOI: 10.1016/j.ophtha.2013.08.011.
7.	Monés J, Srivastava SK, Jaffe GJ, et al. Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with Brolucizumab: post Hoc review of HAWK and HARRIER[J]. Ophthalmology, 2021, 128(7): 1050-1059. DOI: 10.1016/j.ophtha.2020.11.011.
8.	Rosenbaum JT, Sibley CH, Lin P. Retinal vasculitis[J]. Curr Opin Rheumatol, 2016, 28(3): 228-235. DOI: 10.1097/BOR.0000000000000271.
9.	Abroug N, Khairallah M, Ksiaa I, et al. A comparative study between occlusive and non-occlusive retinal vasculitis: data from a referral center in Tunisia, North Africa[J]. Ocul Immunol Inflamm, 2023, 31(1): 97-104. DOI: 10.1080/09273948.2021.1986726.
10.	Arepalli SR, Thomas AS. Occlusive retinal vasculitis: novel insights into causes, pathogenesis and treatment[J]. Curr Opin Ophthalmol, 2022, 33(3): 147-156. DOI: 10.1097/ICU.0000000000000843.
11.	Servillo A, Cicinelli MV, Mularoni C, et al. Drug-induced vasculitis and choroiditis after Brolucizumab[J]. Ophthalmology Retina, 2025, 9(10): 1023-1025. DOI: 10.1016/j.oret.2025.05.020.
12.	Lee YM, Gurung R, Gilhotra JS, et al. Bilateral occlusive retinal vasculitis secondary to intravitreal Faricimab injection: a case report and review of literature[J/OL]. Eye Vis (Lond), 2024, 11(1): 48[2024-12-03]. https://pubmed.ncbi.nlm.nih.gov/39627894/. DOI: 10.1186/s40662-024-00416-y.
13.	Cox JT, Eliott D, Sobrin L. Inflammatory complications of intravitreal anti-VEGF injections[J/OL]. J Clin Med, 2021, 10(5): 981[2021-03-02]. https://pubmed.ncbi.nlm.nih.gov/33801185/. DOI: 10.3390/jcm10050981.
14.	Anderson WJ, da Cruz NFS, Lima LH, et al. Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review[J/OL]. Int J Retina Vitreous, 2021, 7(1): 37[2021-05-07]. https://pubmed.ncbi.nlm.nih.gov/33962696/. DOI: 10.1186/s40942-021-00307-7.
15.	Hoffmann L, Michels S, Eandi C, et al. Aflibercept high-dose (8 mg) related intraocular inflammation (IOI)-a case series[J/OL]. BMC Ophthalmol, 2024, 24(1): 520[2024-12-02]. https://pubmed.ncbi.nlm.nih.gov/39623439/. DOI: 10.1186/s12886-024-03788-w.
16.	Ma P, Pan X, Liu R, et al. Ocular adverse events associated with anti-VEGF therapy: a pharmacovigilance study of the FDA adverse event reporting system (FAERS)[J/OL]. Front Pharmacol, 2022, 13: 1017889[2022-11-18]. https://pubmed.ncbi.nlm.nih.gov/36467087/. DOI: 10.3389/fphar.2022.1017889.
17.	Ng DSC, Ho M, Iu LPL, et al. Safety review of anti-VEGF therapy in patients with myopic choroidal neovascularization[J]. Expert Opin Drug Saf, 2022, 21(1): 43-54. DOI: 10.1080/14740338.2021.1952979.
18.	Bruening W, Kim S, Yeh S, et al. Inflammation and occlusive retinal vasculitis post Faricimab[J]. JAMA Ophthalmol, 2025, 143(3): 232-235. DOI: 10.1001/jamaophthalmol.2024.5889.
19.	Baumal CR, Spaide RF, Vajzovic L, et al. Retinal vasculitis and intraocular inflammation after intravitreal injection of Brolucizumab[J]. Ophthalmology, 2020, 127(10): 1345-1359. DOI: 10.1016/j.ophtha.2020.04.017.
20.	Sisk RA. Occlusive retinal vasculitis after Aflibercept 8 mg injection for wet macular degeneration[J/OL]. Retin Cases Brief Rep, 2025, 2025: E1(2025-11-07)[2025-04-02]. https://pubmed.ncbi.nlm.nih.gov/40184546/. DOI: 10.1097/ICB.0000000000001757. [published online ahead of print].

1. Bagheri S, Ntentakis DP, Emfietzoglou M, et al. Sterile intraocular inflammation following intravitreal injections: pathogenesis, clinical features, and management[J]. Int Ophthalmol Clin, 2025, 65(3): 63-70. DOI: 10.1097/IIO.0000000000000580.
2. Ferreira AM, Mendes AF, Beato JN, et al. Intraocular inflammation following intravitreal injections of anti-vascular endothelial growth factor drugs[J]. Graefe's Arch Clin Exp Ophthalmol, 2025, 263(10): 2885-2892. DOI: 10.1007/s00417-025-06875-w.
3. 中華醫學會眼科學分會眼底病學組, 中國醫師協會眼科醫師分會眼底病專業委員會, 《眼內注藥治療后非感染性眼內炎癥診療專家共識(2025)》專家組. 眼內注藥治療后非感染性眼內炎癥診療專家共識(2025)[J]. 中華眼底病雜志, 2025, 41(7): 492-506. DOI: 10.3760/cma.j.cn511434-20250617-00274.Fundus Disease Group of Ophthalmological Society of Chinese Medical Association, Fundus Disease Group of Ophthalmologist Branch of Chinese Medical Doctor Association, Expert Group of Expert Consensus for the Diagnosis Treatment of SterileIntraocular Inflammation after Intraocular Drug Delivery (2025). Expert consensus for the diagnosis and treatment of sterile intraocular inflammation after intraocular drug delivery (2025)[J]. Chin J Ocul Fundus Dis, 2025, 41(7): 492-506. DOI: 10.3760/cma.j.cn511434-20250617-00274.
4. Weisbrod DJ, Kertes PJ. Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials[J]. Arch Ophthalmol, 2009, 127(2): 1581-1583. DOI: 10.1001/archophthalmol.2009.304.
5. Goldberg RA, Shah CP, Wiegand TW, et al. Noninfectious inflammation after intravitreal injection of Aflibercept: clinical characteristics and visual outcomes[J]. Am J Ophthalmol, 2014, 158(4): 733-737. DOI: 10.1016/j.ajo.2014.06.019.
6. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies[J]. Ophthalmology, 2014, 121(1): 193-201. DOI: 10.1016/j.ophtha.2013.08.011.
7. Monés J, Srivastava SK, Jaffe GJ, et al. Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with Brolucizumab: post Hoc review of HAWK and HARRIER[J]. Ophthalmology, 2021, 128(7): 1050-1059. DOI: 10.1016/j.ophtha.2020.11.011.
8. Rosenbaum JT, Sibley CH, Lin P. Retinal vasculitis[J]. Curr Opin Rheumatol, 2016, 28(3): 228-235. DOI: 10.1097/BOR.0000000000000271.
9. Abroug N, Khairallah M, Ksiaa I, et al. A comparative study between occlusive and non-occlusive retinal vasculitis: data from a referral center in Tunisia, North Africa[J]. Ocul Immunol Inflamm, 2023, 31(1): 97-104. DOI: 10.1080/09273948.2021.1986726.
10. Arepalli SR, Thomas AS. Occlusive retinal vasculitis: novel insights into causes, pathogenesis and treatment[J]. Curr Opin Ophthalmol, 2022, 33(3): 147-156. DOI: 10.1097/ICU.0000000000000843.
11. Servillo A, Cicinelli MV, Mularoni C, et al. Drug-induced vasculitis and choroiditis after Brolucizumab[J]. Ophthalmology Retina, 2025, 9(10): 1023-1025. DOI: 10.1016/j.oret.2025.05.020.
12. Lee YM, Gurung R, Gilhotra JS, et al. Bilateral occlusive retinal vasculitis secondary to intravitreal Faricimab injection: a case report and review of literature[J/OL]. Eye Vis (Lond), 2024, 11(1): 48[2024-12-03]. https://pubmed.ncbi.nlm.nih.gov/39627894/. DOI: 10.1186/s40662-024-00416-y.
13. Cox JT, Eliott D, Sobrin L. Inflammatory complications of intravitreal anti-VEGF injections[J/OL]. J Clin Med, 2021, 10(5): 981[2021-03-02]. https://pubmed.ncbi.nlm.nih.gov/33801185/. DOI: 10.3390/jcm10050981.
14. Anderson WJ, da Cruz NFS, Lima LH, et al. Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review[J/OL]. Int J Retina Vitreous, 2021, 7(1): 37[2021-05-07]. https://pubmed.ncbi.nlm.nih.gov/33962696/. DOI: 10.1186/s40942-021-00307-7.
15. Hoffmann L, Michels S, Eandi C, et al. Aflibercept high-dose (8 mg) related intraocular inflammation (IOI)-a case series[J/OL]. BMC Ophthalmol, 2024, 24(1): 520[2024-12-02]. https://pubmed.ncbi.nlm.nih.gov/39623439/. DOI: 10.1186/s12886-024-03788-w.
16. Ma P, Pan X, Liu R, et al. Ocular adverse events associated with anti-VEGF therapy: a pharmacovigilance study of the FDA adverse event reporting system (FAERS)[J/OL]. Front Pharmacol, 2022, 13: 1017889[2022-11-18]. https://pubmed.ncbi.nlm.nih.gov/36467087/. DOI: 10.3389/fphar.2022.1017889.
17. Ng DSC, Ho M, Iu LPL, et al. Safety review of anti-VEGF therapy in patients with myopic choroidal neovascularization[J]. Expert Opin Drug Saf, 2022, 21(1): 43-54. DOI: 10.1080/14740338.2021.1952979.
18. Bruening W, Kim S, Yeh S, et al. Inflammation and occlusive retinal vasculitis post Faricimab[J]. JAMA Ophthalmol, 2025, 143(3): 232-235. DOI: 10.1001/jamaophthalmol.2024.5889.
19. Baumal CR, Spaide RF, Vajzovic L, et al. Retinal vasculitis and intraocular inflammation after intravitreal injection of Brolucizumab[J]. Ophthalmology, 2020, 127(10): 1345-1359. DOI: 10.1016/j.ophtha.2020.04.017.
20. Sisk RA. Occlusive retinal vasculitis after Aflibercept 8 mg injection for wet macular degeneration[J/OL]. Retin Cases Brief Rep, 2025, 2025: E1(2025-11-07)[2025-04-02]. https://pubmed.ncbi.nlm.nih.gov/40184546/. DOI: 10.1097/ICB.0000000000001757. [published online ahead of print].

Previous Article
雙眼乙型肝炎相關性視神經炎1例
Next Article
先天性視網膜動靜脈畸形1例

Chinese Journal of Ocular Fundus Diseases

玻璃體腔注射抗血管內皮生長因子藥物治療相關非感染性視網膜血管炎1例

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content